Replimune to Participate at the SVB Leerink Oncology 1x1 Day
Replimune Group Inc. (Nasdaq: REPL) announced its senior management team's participation in investor meetings at the SVB Leerink Oncology 1x1 Day on November 19, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Replimune Group Inc. (Nasdaq: REPL) announced its senior management team's participation in investor meetings at the SVB Leerink Oncology 1x1 Day on November 19, 2020. The biotechnology company, based in Woburn, MA, focuses on developing oncolytic immuno-gene therapies from its Immulytic™ platform. This innovative approach aims to enhance cancer treatment by leveraging virus replication and immune response to tumor antigens. Replimune's goal is to advance these therapies through clinical development, working alongside other immuno-oncology treatments.
Details
News Market Reaction – REPL
The recorded move for REPL in the trading session of this news was -5.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1x1 Day being held on Thursday, November 19, 2020.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com.
Replimune Contact
Pamela Esposito, Ph.D.
Replimune Group Inc.
pamela@replimune.com
Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.